title: The effects of the novel DA D3 receptor antagonist SR 21502 on cocaine reward, cocaine seeking and cocaine-induced locomotor activity in rats.
abstract: BACKGROUND
  There is a focus on developing D3 receptor antagonists as cocaine addiction treatments.
  
  
  OBJECTIVE
  We investigated the effects of a novel selective D3 receptor antagonist, SR 21502, on cocaine reward, cocaine-seeking, food reward, spontaneous locomotor activity and cocaine-induced locomotor activity in rats.
  
  
  METHODS
  In Experiment 1, rats were trained to self-administer cocaine under a progressive ratio (PR) schedule of reinforcement and tested with vehicle or one of three doses of SR 21502. In Experiment 2, animals were trained to self-administer cocaine under a fixed ratio schedule of reinforcement followed by extinction of the response. Then, animals were tested with vehicle or one of the SR 21502 doses on cue-induced reinstatement of responding. In Experiment 3, animals were trained to lever press for food under a PR schedule and tested with vehicle or one dose of the compound. In Experiments 4 and 5, in separate groups of animals, the vehicle and three doses of SR 21502 were tested on spontaneous or cocaine (10 mg/kg, IP)-induced locomotor activity, respectively.
  
  
  RESULTS
  SR 21502 produced significant, dose-related (3.75, 7.5 and 15 mg/kg) reductions in breakpoint for cocaine self-administration, cue-induced reinstatement (3.75, 7.5 and 15 mg/kg) and cocaine-induced locomotor activity (3.75, 7.5 and 15 mg/kg) but failed to reduce food self-administration and spontaneous locomotor activity.
  
  
  CONCLUSIONS
  SR 21502 decreases cocaine reward, cocaine-seeking and locomotor activity at doses that have no effect on food reward or spontaneous locomotor activity. These data suggest SR 21502 may selectively inhibit cocaine's rewarding, incentive motivational and stimulant effects.
authors.affiliation: Neuropsychology Doctoral Program, CUNY Graduate Center, New York, NY, USA.
authors.forename: E
authors.initials: E
authors.lastname: Galaj
authors.forename: S
authors.initials: S
authors.lastname: Ananthan
authors.forename: M
authors.initials: M
authors.lastname: Saliba
authors.forename: Robert
authors.initials: R
authors.lastname: Ranaldi
mesh_terms: D000818:Animals; D003042:Cocaine / Q000009:adverse effects; D019970:Cocaine-Related Disorders / Q000188:drug therapy*; D003463:Cues; D018492:Dopamine Antagonists / Q000737:chemistry / Q000494:pharmacology*; D018765:Dopamine Uptake Inhibitors / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D058999:Drug-Seeking Behavior / Q000187:drug effects*; D005108:Extinction, Psychological / Q000187:drug effects; D005247:Feeding Behavior / Q000187:drug effects; D007093:Imidazoles / Q000737:chemistry / Q000494:pharmacology*; D008297:Male; D009043:Motor Activity / Q000187:drug effects*; D011725:Pyridines / Q000737:chemistry / Q000494:pharmacology*; D011897:Random Allocation; D020318:Rats, Long-Evans; D050637:Receptors, Dopamine D3 / Q000037:antagonists & inhibitors*; D012054:Reinforcement, Psychology; D012646:Self Administration
chemical_list: D018492:Dopamine Antagonists; D018765:Dopamine Uptake Inhibitors; D007093:Imidazoles; D011725:Pyridines; D050637:Receptors, Dopamine D3; C000593313:SR 21502; D003042:Cocaine
references.citation: Nature. 1990 Sep 13;347(6289):146-51
references.pmid: 1975644
references.citation: Neuropsychopharmacology. 2006 Jul;31(7):1393-405
references.pmid: 16205781
references.citation: Psychopharmacology (Berl). 1998 Dec;140(3):331-44
references.pmid: 9877013
references.citation: CNS Neurol Disord Drug Targets. 2008 Nov;7(5):410-21
references.pmid: 19128200
references.citation: CNS Drug Rev. 2007 Summer;13(2):240-59
references.pmid: 17627675
references.citation: Bioorg Med Chem Lett. 1998 Oct 6;8(19):2715-8
references.pmid: 9873609
references.citation: Psychopharmacology (Berl). 2004 Oct;176(1):57-65
references.pmid: 15083257
references.citation: J Pharmacol Exp Ther. 1994 Jul;270(1):209-18
references.pmid: 8035317
references.citation: Neuroreport. 2003 Jan 20;14(1):93-8
references.pmid: 12544838
references.citation: NIDA Res Monogr. 1993;137:73-95
references.pmid: 8289929
references.citation: Pharmacol Rev. 2002 Mar;54(1):1-42
references.pmid: 11870259
references.citation: J Neurosci. 2002 Nov 1;22(21):9595-603
references.pmid: 12417684
references.citation: Can J Psychol. 1977 Dec;31(4):195-203
references.pmid: 608135
references.citation: Nat Rev Neurosci. 2004 Jun;5(6):483-94
references.pmid: 15152198
references.citation: J Med Chem. 2003 Nov 6;46(23):4952-64
references.pmid: 14584946
references.citation: Science. 1993 Jun 18;260(5115):1814-6
references.pmid: 8099761
references.citation: Pharmacol Biochem Behav. 2005 Dec;82(4):727-34
references.pmid: 16405981
references.citation: Neurosci Biobehav Rev. 2006;30(2):215-38
references.pmid: 16099045
references.citation: Pharmacol Biochem Behav. 1989 Mar;32(3):691-7
references.pmid: 2662223
references.citation: J Pharmacol Exp Ther. 2010 Jun;333(3):854-64
references.pmid: 20228156
references.citation: J Med Chem. 2005 Feb 10;48(3):839-48
references.pmid: 15689168
references.citation: Brain Res Bull. 2003 Oct 15;61(6):595-601
references.pmid: 14519456
references.citation: Neuroscience. 1995 Apr;65(3):731-45
references.pmid: 7609872
references.citation: Curr Opin Neurobiol. 1996 Apr;6(2):243-51
references.pmid: 8725967
references.citation: Psychopharmacology (Berl). 1981;75(2):134-43
references.pmid: 6798603
references.citation: J Neurosci. 2000 Dec 1;20(23):8677-84
references.pmid: 11102473
references.citation: Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):11271-5
references.pmid: 7972046
references.citation: Addict Biol. 2012 Mar;17(2):259-73
references.pmid: 21507153
references.citation: Synapse. 2005 Jul;57(1):17-28
references.pmid: 15858839
references.citation: NIDA Res Monogr. 1988;81:74-80
references.pmid: 3136393
references.citation: Nature. 1999 Jul 22;400(6742):371-5
references.pmid: 10432116
references.citation: Neuropharmacology. 2009 Mar;56(4):752-60
references.pmid: 19136017
references.citation: J Neurosci Methods. 1996 May;66(1):1-11
references.pmid: 8794935
references.citation: J Neurosci. 2001 Aug 1;21(15):5841-6
references.pmid: 11466456
references.citation: J Med Chem. 2007 Oct 18;50(21):5076-89
references.pmid: 17867665
references.citation: Eur J Neurosci. 2005 Jun;21(12):3427-38
references.pmid: 16026480
references.citation: Psychopharmacology (Berl). 2002 Oct;163(3-4):265-82
references.pmid: 12373428
references.citation: Ann N Y Acad Sci. 2010 Feb;1187:4-34
references.pmid: 20201845
references.citation: J Med Chem. 2007 Aug 23;50(17):4135-46
references.pmid: 17672446
references.citation: Psychopharmacology (Berl). 1992;107(4):523-9
references.pmid: 1603895
references.citation: Psychopharmacology (Berl). 1982;78(3):204-9
references.pmid: 6296898
references.citation: Behav Pharmacol. 2011 Aug;22(4):347-53
references.pmid: 21673566
references.citation: J Comp Neurol. 2005 Dec 5;493(1):115-21
references.pmid: 16254990
references.citation: Curr Top Behav Neurosci. 2010;3:29-71
references.pmid: 21161749